BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16181035)

  • 1. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
    Thieringer R; Hermanowski-Vosatka A
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):911-24. PubMed ID: 16181035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW; Stewart PM
    Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD; Azevedo I; Monteiro R; Martins MJ
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
    Wang M
    Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
    Boyle CD; Kowalski TJ
    Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the discovery of 11beta-HSD1 inhibitors.
    Boyle CD
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
    Gu X; Dragovic J; Koo GC; Koprak SL; LeGrand C; Mundt SS; Shah K; Springer MS; Tan EY; Thieringer R; Hermanowski-Vosatka A; Zokian HJ; Balkovec JM; Waddell ST
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5266-9. PubMed ID: 16185866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
    Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
    J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortisol--cause and cure for metabolic syndrome?
    Walker BR
    Diabet Med; 2006 Dec; 23(12):1281-8. PubMed ID: 17116176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM
    Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Aster SD; Graham DW; Kharbanda D; Patel G; Ponpipom M; Santorelli GM; Szymonifka MJ; Mundt SS; Shah K; Springer MS; Thieringer R; Hermanowski-Vosatka A; Wright SD; Xiao J; Zokian H; Balkovec JM
    Bioorg Med Chem Lett; 2008 May; 18(9):2799-804. PubMed ID: 18434143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Odermatt A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.